SCHEMBL2038199

SCHEMBL2038199

Oc1ccc(F)cc1CNc1ccnc(Br)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
ANO1 Q5XXA6 5/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
ALOX12 P18054 1/20 0.43
MPI P34949 1/20 0.43
RECQL P46063 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
APP P05067 1/20 0.43
EGFR P00533 2/20 0.42
POLB P06746 1/20 0.42
PLEC Q15149 1/20 0.42
CASP6 P55212 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2037130 0.83 ANO1 (0.46) KDM4EKMT2AMEN1ANO1ALDH1A1
SCHEMBL2038341 0.81 MAPT (0.54) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL2039704 0.78 KMT2A (0.43) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL2042919 0.76 MEN1 (0.41) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL2048102 0.75 KMT2A (0.50) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL20376006 0.74 MAOB (0.56) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL2042255 0.72 NPSR1 (0.50) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL27770274 0.70 EGFR (0.74) ALDH1A1MAPTTDP1EGFRSYK
SCHEMBL27770271 0.69 EGFR (0.60) ALDH1A1MAPTTDP1APPEGFR
SCHEMBL25442715 0.69 EGFR (0.51) KDM4EKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-02-12 US claimed
EP-2516400-B1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2017-03-22 EP claimed
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-11 US claimed
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-02-12 US disclosed
EP-2516400-B1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2017-03-22 EP disclosed
US-20160068488-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF COLLETTE PATRICE LUCIEN MAURICE (FR) 2016-03-10 US disclosed
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-11 US disclosed
EP-2516400-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP disclosed
WO-2011077046-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068488-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA KDM4E 1507/4885KMT2A 2277/4885MEN1 3059/4885
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA KDM4E 1507/4885KMT2A 2277/4885MEN1 3059/4885
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof TYR, MITF, CUTA KDM4E 1507/4885KMT2A 2277/4885MEN1 3059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.